Advertisement
Advertisement
-
Money /
Money News
Related Topics:
Banking & finance
Made in China 2025
After boost from viral dance challenge, Chinese medicine firm’s shares languish
Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.
22 Feb 2026 - 2:00PM
IPO
Shenzhen-listed Unisplendour abandons plan to raise funds in Hong Kong
12 Feb 2026 - 8:00AM
Made in China 2025
Capital injection: China backs AI drug makers in self-reliance drive
11 Feb 2026 - 5:14PM
Made in China 2025
Chinese healthcare firms expand overseas to support growing expat community
Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.
11 Feb 2026 - 5:08PM
Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Banking & finance
Mainland China’s investors pour into Hong Kong-listed drug stocks
An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.
10 Feb 2026 - 4:31PM
Banking & finance
China slashes wait times for loss-making tech firms seeking refinancing, fundraising
Three of China’s stock exchanges have relaxed fundraising time thresholds on listed tech companies as Beijing pushes for self-reliance.
10 Feb 2026 - 11:26AM
videocam
Advertisement
Advertisement
Advertisement
Made in China 2025
Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal
The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.
6 Feb 2026 - 5:00PM
A view of the Shanghai facility of Fosun Pharma’s biopharma unit Henlius. Photo: Handout
IPO
Morgan Stanley sees another record year for Hong Kong IPOs as pipeline hits 450
Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.
5 Feb 2026 - 7:35AM
Banking & finance
Chinese gold, silver investors face gut check amid volatility, fund suspensions
Some retreat to the sidelines as another fund suspends new investments and futures plunge, while others remain determined to buy the dip.
3 Feb 2026 - 9:54AM
Banking & finance
Global funds, from BlackRock to Temasek, back China’s largest biotech firms
Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.
23 Jan 2026 - 8:30AM
Biomedicine: Industry Trends
Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout
Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.
21 Jan 2026 - 7:43AM
Global drug companies no longer view Chinese firms as contract manufacturers, but as development partners, an analyst says. Photo: Shutterstock
Made in China 2025
Exclusive
|
China challenges US in AI drug race, but rivals still reliant on each other
While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.
20 Jan 2026 - 11:16AM
Banking & finance
SF Holding, J&T strike US$1 billion deal as Asian e-commerce booms
The agreement will help SF Holding expand its international businesses, according to the Shenzhen-based company.
15 Jan 2026 - 4:57PM
Made in China 2025
Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s
SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.
13 Jan 2026 - 2:02PM
videocam
Made in China 2025
China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens
Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.
13 Jan 2026 - 7:30AM
There were more than 400 million overweight or obese adults in China in 2021, according to a study. Photo: Getty Images
Banking & finance
TCM firms eye Hong Kong IPOs to fuel global expansion
Over the past year, 34 innovation and technology, life and health science companies set up or expanded their operations in Hong Kong.
8 Jan 2026 - 7:54PM
Made in China 2025
Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025
Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.
8 Jan 2026 - 8:30AM
Advertisement
Advertisement
Advertisement
Made in China 2025
Meow or never: China’s pudgy pets spark race for weight-loss drugs
Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.
7 Jan 2026 - 8:30AM
The total pet population in China reached 430 million in 2024, with nearly one-third of urban cats classified as obese, according to the China Pet Industry Association. Photo: Shutterstock
Banking & finance
Citic Securities claims top spot in Asia-Pacific investment banking for 2025
Chinese rivals fill out the rest of the top five, while US bank Morgan Stanley comes in sixth.
6 Jan 2026 - 8:56PM
Banking & finance
The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs
A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.
5 Jan 2026 - 11:08AM
IPO
China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs
US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.
31 Dec 2025 - 2:26PM
Made in China 2025
China’s rising biotech clout on show in flurry of billion-dollar licensing deals
A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.
26 Dec 2025 - 10:47AM
The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
Swire Group
Swire Pacific’s Guy Bradley to lead Hong Kong’s Cathay Pacific, Swire Coca-Cola
Bradley succeeds Patrick Healy, who will retire from the Swire Group in May next year after over three decades of service.
23 Dec 2025 - 10:19PM
Banking & finance
Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG
Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.
23 Dec 2025 - 9:30AM
Banking & finance
Gold takes centre stage as Hong Kong builds commodities ecosystem
Hong Kong plans to build an international gold trading centre as part of a wider commodities hub push.
22 Dec 2025 - 7:15PM
Help preserve 120 years of quality journalism.
SUPPORT NOW
